Solventum Corporation (SOLV) Stock Price, Quote & News

Company Profile

Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temp...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Website: www.solventum.com

Address:

1750 Yankee Doodle Road, Eagan, United States

Robb88 May. 12 at 6:14 AM

$SOLV

0 · Reply

CapitalMonk May. 12 at 3:20 AM

$SOLV Price: $74.12 (+1.01%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.48% RSI: 67.9 | Momentum: Moderate Volume: +15.2% vs avg Volatility: 1.65% Support: $65.44 | Resistance: $74.20 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

OpenOutcrier May. 6 at 12:32 PM

$SOLV (-2.8% pre) Solventum (NYSE:SOLV) Exceeds Q1 CY2026 Expectations https://ooc.bz/l/101261

0 · Reply

StocktwitsEarnings May. 5 at 8:15 PM

$SOLV Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.07 down -91.14% YoY • Reported revenue of $2.01B down -3.04% YoY • Solventum affirmed full-year 2026 organic sales growth guidance of +2.0% to +3.0% and estimates adjusted diluted EPS will be toward the high end of the $6.40 to $6.60 range.

0 · Reply

bigbulldaddy May. 2 at 3:13 PM

$SOLV https://www.globenewswire.com/news-release/2026/04/30/3285301/0/en/trian-calls-on-solventum-s-board-to-create-value-publishes-open-letter-and-slide-deck.html Have to agree with a lot of this view point. HIS could become valuable or get completely replaced by newer AI programs. Harder to sell for max value now in the current software environment but I would say that risk only increases from here with time. We laid off an entire role and are forcing reps to do as much as 2x the work with no additional pay. Many reps have one foot in and one foot out of the company. Restrata/Ascera will bring value but slower than anticipated at the value we paid for it. They seem content to hold their employees down while desperately looking for funds to buy more companies. That doesn’t seem like a solid long term strategy. People are in roles they weren’t ready for. Training is inadequate. Moral amongst employees is breaking and there isn’t a fast enough plan to fix it. Stock is flat

0 · Reply

LongLTC May. 1 at 2:47 AM

$SOLV Hard to believe the market has missed this gem! I am accumulating at these levels!

0 · Reply

OpenOutcrier Apr. 30 at 8:00 PM

RECAP 4/30 Chatter: $AXSM + Auvelity approved $SOLV + Trian $SKBL + Trump Sons Stake Live Breaking trading news www.openoutcrier.com

0 · Reply

SuperGreenToday Apr. 30 at 7:41 PM

$SOLV Share Price: $67.34 Contract Selected: Oct 16, 2026 $65 Calls Buy Zone: $5.78 – $7.14 Target Zone: $9.59 – $11.72 Potential Upside: 57% ROI Time to Expiration: 168 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Robb88 Apr. 29 at 3:10 AM

$EIGEN.X dont sleep on this and $SOLV

1 · Reply

luckymox Mar. 23 at 6:19 PM

$SOLV should be some decent support in this range

0 · Reply

Solventum to Participate in the 2026 BofA Securities Health Care Conference

May 5, 2026, 6:14 PM EDT - 7 days ago

Solventum forecasts annual profit at higher end on wound care demand

May 5, 2026, 4:05 PM EDT - 7 days ago

Solventum Reports First Quarter 2026 Financial Results

May 1, 2026, 6:15 AM EDT - 12 days ago

Peltz's Trian urges Solventum to rightsize costs, divest non-core businesses

Apr 30, 2026, 1:05 PM EDT - 13 days ago

Trian Calls on Solventum's Board to Create Value; Publishes Open Letter and Slide Deck

Apr 14, 2026, 4:05 PM EDT - 4 weeks ago

Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026

Mar 11, 2026, 4:05 PM EDT - 2 months ago

Solventum to Participate in the 2026 KeyBanc Healthcare Forum

Feb 26, 2026, 4:43 PM EST - 2 months ago

Solventum beats quarterly estimates on strong demand for surgical products

Feb 26, 2026, 4:05 PM EST - 2 months ago

Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance

Feb 3, 2026, 4:05 PM EST - 3 months ago

Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026

Dec 23, 2025, 4:05 PM EST - 5 months ago

Solventum Completes Acquisition of Acera Surgical

Dec 17, 2025, 4:05 PM EST - 5 months ago

Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy

Dec 16, 2025, 4:05 PM EST - 5 months ago

Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength

Nov 25, 2025, 4:05 PM EST - 6 months ago

Solventum to Participate in the 2025 Piper Sandler Healthcare Conference

Nov 20, 2025, 9:00 AM EST - 6 months ago

Solventum Announces $1 Billion Share Repurchase Program

Nov 20, 2025, 9:00 AM EST - 6 months ago

Solventum Announces Agreement to Acquire Acera Surgical

Nov 6, 2025, 4:05 PM EST - 6 months ago

Solventum Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:05 PM EST - 6 months ago

Solventum to Participate in the 2025 Stifel Healthcare Conference

Oct 21, 2025, 5:00 PM EDT - 7 months ago

Solventum Appoints Heather Knight as Chief Commercial Officer

Oct 16, 2025, 4:05 PM EDT - 7 months ago

Solventum to Report Third Quarter Fiscal 2025 Earnings on November 6, 2025

Sep 8, 2025, 2:30 PM EDT - 8 months ago

Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers

Sep 8, 2025, 8:30 AM EDT - 8 months ago

Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Solventum Completes Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc.

TMO

Sep 2, 2025, 8:00 AM EDT - 9 months ago

Thermo Fisher Scientific Completes Acquisition of Solventum's Purification and Filtration Business

TMO

Aug 28, 2025, 4:05 PM EDT - 9 months ago

Solventum to Participate in Upcoming Investor Conferences

Aug 22, 2025, 8:19 AM EDT - 9 months ago

Solventum Announces $1.75 Billion Note Tender Offers

Aug 13, 2025, 10:39 PM EDT - 9 months ago

Solventum Announces Pricing of Secondary Offering of Common Stock

Aug 13, 2025, 4:48 PM EDT - 9 months ago

Solventum Announces Launch of Secondary Offering of Common Stock

Aug 7, 2025, 4:52 PM EDT - 9 months ago

Solventum raises annual profit forecast on strength in surgical equipment

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Solventum Reports Second Quarter 2025 Financial Results

Jul 17, 2025, 4:05 PM EDT - 10 months ago

Solventum to Report Second Quarter Fiscal 2025 Earnings on August 7, 2025

Jun 18, 2025, 10:00 AM EDT - 11 months ago

Solventum Named a Best Company to Work for by U.S. News & World Report

Jun 3, 2025, 4:05 PM EDT - 1 year ago

Solventum to Participate in the 2025 Goldman Sachs Health Care Conference

May 8, 2025, 6:11 PM EDT - 1 year ago

Solventum beats first-quarter profit estimates on strong surgical product sales

May 8, 2025, 4:05 PM EDT - 1 year ago

Solventum to Participate in the 2025 BofA Securities Health Care Conference

May 8, 2025, 4:05 PM EDT - 1 year ago

Solventum Reports First Quarter 2025 Financial Results

Apr 17, 2025, 4:05 PM EDT - 1 year ago

Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025

Mar 25, 2025, 6:00 PM EDT - 1 year ago

Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations

Mar 20, 2025, 9:00 AM EDT - 1 year ago

Solventum to Present Value Creation Formula and Long-Range Plan at 2025 Investor Day

Mar 12, 2025, 8:12 AM EDT - 1 year ago

Solventum Launches Attest™ eBowie-Dick Test System Revolutionizing Sterilization Assurance

Feb 27, 2025, 5:09 PM EST - 1 year ago

Solventum forecasts annual profit above estimates on strong surgical product sales

Feb 27, 2025, 4:05 PM EST - 1 year ago

Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance

Feb 26, 2025, 4:15 PM EST - 1 year ago

Solventum to Host Investor Day on Thursday, March 20, 2025, in New York City

Feb 26, 2025, 3:37 PM EST - 1 year ago

Nelson Peltz's Trian to push Solventum to further simplify business, WSJ reports

Feb 26, 2025, 2:50 PM EST - 1 year ago

Trian Comments on Solventum's Sale of its Purification & Filtration Business

TMO

Feb 25, 2025, 8:56 AM EST - 1 year ago

Thermo Fisher buys Solventum's purification and filtration business for $4.1 billion

TMO

Feb 25, 2025, 8:39 AM EST - 1 year ago

Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

TMO

Feb 25, 2025, 8:32 AM EST - 1 year ago

Thermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business

TMO

Feb 11, 2025, 8:00 AM EST - 1 year ago

Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

Feb 5, 2025, 10:00 AM EST - 1 year ago

Solventum Fluency for Imaging clinches top spot again: Ranked #1 Best in KLAS for Speech Recognition: Front-end Imaging

Robb88 May. 12 at 6:14 AM

$SOLV

0 · Reply

CapitalMonk May. 12 at 3:20 AM

0 · Reply

OpenOutcrier May. 6 at 12:32 PM

$SOLV (-2.8% pre) Solventum (NYSE:SOLV) Exceeds Q1 CY2026 Expectations https://ooc.bz/l/101261

0 · Reply

StocktwitsEarnings May. 5 at 8:15 PM

0 · Reply

bigbulldaddy May. 2 at 3:13 PM

0 · Reply

LongLTC May. 1 at 2:47 AM

$SOLV Hard to believe the market has missed this gem! I am accumulating at these levels!

0 · Reply

OpenOutcrier Apr. 30 at 8:00 PM

RECAP 4/30 Chatter: $AXSM + Auvelity approved $SOLV + Trian $SKBL + Trump Sons Stake Live Breaking trading news www.openoutcrier.com

0 · Reply

SuperGreenToday Apr. 30 at 7:41 PM

0 · Reply

Robb88 Apr. 29 at 3:10 AM

$EIGEN.X dont sleep on this and $SOLV

1 · Reply

luckymox Mar. 23 at 6:19 PM

$SOLV should be some decent support in this range

0 · Reply

Boston7452 Mar. 21 at 5:31 PM

$SOLV best chance for significant revenue growth, i believe, will come for its Medsurg division. All it needs to do is bring new mask products, PPE, air filtration, and woundcare products with Anti-viral/Anti-bacteria capabilities to market before the next pandemic. Current estimates for the next pandemic is late 2027 / early 2028. Pandemic maybe 1 or more respiratory viruses circulating at the same time like we saw this winter with so many schools shutting down due to amount of teachers/students out sick.

1 · Reply

OfficialStocktwitsUser Mar. 10 at 11:02 PM

$SOLV RSI: 28.05, MACD: -2.3810 Vol: 3.56, MA20: 73.58, MA50: 77.28 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

1 · Reply

Estimize Mar. 9 at 12:00 PM

Wall St is expecting 1.35 EPS for $SOLV Q1 [Reporting 05/07 AMC] http://www.estimize.com/intro/solv?chart=historical&metric_name=eps&utm_co

0 · Reply

bigbulldaddy Mar. 2 at 2:41 PM

$SOLV Restrata integration appears slower than anticipated. Company also has a huge risk in HIS business over next 3-5 years with other SAAS AI plays ramping up. Could result in a large portion of the SOLV business/revenue breaking down. Company appears to be making AI plays itself with help from google/amazon. Obsolescence risks identified as chat bots and LLMs become comoditized.

0 · Reply

ZacksResearch Feb. 27 at 7:44 PM

$SOLV beats Q4 estimates, but shares dip 2.5% post-earnings. Why? 🤔 🔍 EPS of $1.57 topped estimates by 4.7%, marking an 11.3% year over year improvement 📈 Revenue climbed 3.7% reportedly with strong MedSurg & Dental Solutions driving organic growth See the full analysis here 👉 https://www.zacks.com/stock/news/2877011/solventum-stock-down-despite-q4-earnings-revenues-beat-margins-down?cid=sm-stocktwits-2-2877011-body-35653&ADID=SYND_STOCKTWITS_TWEET_2_2877011_BODY_35653

0 · Reply

ZacksResearch Feb. 27 at 6:44 PM

$SOLV beats… and still gets sold. ⚠️ Q4 earnings and revenues topped estimates, powered by organic growth across MedSurg, Dental and HIS — but margins declined, and that’s what the market is zeroing in on. Growth is there, but margin pressure is the swing factor. See the full breakdown here 👉 https://www.zacks.com/stock/news/2877011/solventum-stock-down-despite-q4-earnings-revenues-beat-margins-down?cid=sm-stocktwits-2-2877011-teaser-35635&ADID=SYND_STOCKTWITS_TWEET_2_2877011_TEASER_35635

0 · Reply

StocktwitsEarnings Feb. 26 at 9:16 PM

$SOLV Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.36 up 111.76% YoY • Reported revenue of $2B down -3.71% YoY • Solventum anticipates full-year 2026 organic sales growth of +2.0% to +3.0%, or +3.0% to +4.0% excluding SKU exit impact. Solventum also expects adjusted EPS of $6.40 to $6.60 and free cash flow of approximately $200 million.

0 · Reply

Estimize Feb. 25 at 1:36 AM

Wall St is expecting 1.49 EPS for $SOLV Q4 [Reporting 02/26 AMC] http://www.estimize.com/intro/solv?chart=historical&metric_name=eps&utm_co

0 · Reply

ZacksResearch Feb. 23 at 2:15 PM

$SOLV Q4 earnings preview: Will tariffs dampen the momentum? 🧐 Solventum's set to announce Q4 results after market close on Feb. 26. While volume growth and cost initiatives drive optimism, tariff headwinds could weigh on margins. The combination of a positive Earnings ESP and a Zacks Rank #1, 2 or 3 increases chances of an earnings beat, but this isn't the case here. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2873298/solventum-to-post-q4-earnings-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2873298-body-34559&ADID=SYND_STOCKTWITS_TWEET_2_2873298_BODY_34559

0 · Reply

Market Cap	12.84B
Revenue (ttm)	8.33B
Net Income (ttm)	1.56B
EPS (ttm)	N/A
PE Ratio	11.76
Forward PE	11.15
Profit Margin	18.69%
Debt to Equity Ratio	1.02

Volume	1,087,069
Avg Vol	1,406,686
Day's Range	N/A - N/A
Shares Out	173.18M
Stochastic %K	92%
Beta	0.59
Analysts	Sell
Price Target	$83.50